Author:
Počekovac Miloš,Davidović Kristina,Stojanović Mirjana,Stojanović Milena,Mihajlović Slađana,Marković Slađana,Paskaš Jovo
Abstract
Due to its frequency, morbidity and mortality, breast cancer represents the most significant malignancy in women. Oestrogen and progesterone receptor status is used as an important prognostic and predictive factor in breast cancer. The purpose of this research was to determine estrogen and progesterone receptor status of primary breast cancer relative to patient age. High receptor level indicates an active response to endocrine therapy. Studies have shown that about 70% of breast cancers are oestrogen receptor positive, while 30% are negative. The study encompassed 337 patients operated at the Kruševac Regional Centre in the period from 1 January 2011 to 31 December 2013. The patients were classified into four groups according to their hormonal status, after which all groups were tested for certain parameters. All patients had histopathological findings and diagnosis confirmation. Patients with a determined receptor status (329) were divided into four groups depending on the steroid (oestrogen and progesterone) receptor status. Data was analysed with regard to hormonal sensitivity with the patients split into two subgroups: hormone-sensitive and hormone-insensitive. Our results show that 67.65% of the carcinoma were ER+/PR+, 9.19% ER+/PR-, 0.59% ER-/PR+, and 21% ER-/PR-17.21, while 18 women (5.34%) were not tested. Our low percentage of ER-/PRof 17.21% is probably due to the fact that only 18 (5.34%) of the patients were younger than 40. The average share of ER+/PR+, found in our study to be 67.65% goes to over 90% in postmenopausal patients, while the share of ER-/PRamounts to 33.33% in younger patients. The study of oestrogen and progesterone receptor status relative to the patient's age showed that the percentage of patients with ER/PR positive status increases statistically significantly with age and the percentage of hormone insensitive cancers declines, but this decline is not statistically significant.
Publisher
Centre for Evaluation in Education and Science (CEON/CEES)
Reference17 articles.
1. Golddhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes-dealing with the diversity of breast cancer: Highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2011. Ann Oncol. 2011; 22:1736-1747. https://doi.org/10.1093/annonc/mdr304Get;
2. Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, Thürlimann B, Senn HJ; Panel Members. Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol. 2015 Aug;26(8):1533-46. doi: 10.1093/annonc/mdv221. Epub 2015 May 4. PMID: 25939896; PMCID: PMC4511219;
3. MacDonald SM, Haffty BG, Harris ER, Artur DW, Bailey L, Bellon JR et al, ACR Appropriateness Critera locally advanced breast cancer (online publication), Reston (VA): American College of Radiology (ACR); 2011, 13 p.;
4. Jung Kim H. et al. Accuracy of MRI for estimating residual tumor size after neoadjuvant chemotherapy in locally advanced breast cancer. Relation to response patterns on MRI. Acta Oncol 2007; 46:996-1003. https:// doi.org/10.1080/02841860701373587;
5. Hammond MEN. Hormone receptors in breast cancer: Clinical utility and guideline recommendetations to improve test accuracy. In Vors SR, ed. Up to Date. Waltham, Mass: Up to Date, 2021, https:/www.uptodate. com. Last updated August 16, 2021. Accessed August 31, 2021.;